R3HDM4 Inhibitors
Chemical inhibitors of R3HDM4 can impede the protein's function through various biochemical mechanisms, each tied to the protein's role in RNA metabolism and cell cycle regulation. Alsterpaullone and Roscovitine, as cyclin-dependent kinase (CDK) inhibitors, can halt the cell cycle at specific checkpoints, potentially inhibiting R3HDM4 activity that is contingent on cell cycle progression. Likewise, Flavopiridol and DRB target transcription elongation factors, such as P-TEFb, which are crucial for RNA polymerase II's function. By inhibiting these factors, the transcriptional landscape in which R3HDM4 operates is altered, potentially reducing the protein's ability to bind or process RNA. Compounds like 5-Iodotubercidin increase intracellular adenosine levels, which can affect RNA metabolism and thus, R3HDM4's associated functions. Indirubin-3'-monoxime and Harmine inhibit kinases such as GSK-3β and DYRKs, respectively, which are involved in phosphorylation events that can regulate RNA splicing-a process R3HDM4 is likely to influence.
The inhibition of R3HDM4 by kinase inhibitors extends to compounds such as H-89, which targets protein kinase A, affecting numerous downstream pathways, including those governing RNA processing, where R3HDM4 may be essential. Wortmannin and LY294002, as phosphatidylinositol 3-kinase (PI3K) inhibitors, disrupt PI3K signaling, which impacts a broad spectrum of cellular processes, including those involving RNA metabolism that could be mediated by R3HDM4. Staurosporine, a broad-spectrum protein kinase inhibitor, and K252a, which targets a wide range of kinases involved in signal transduction, can also disrupt phosphorylation events critical for RNA metabolic processes linked with R3HDM4. Furthermore, inhibitors of specific signaling pathways such as SP600125, PD98059, U0126, and SB203580 selectively target JNK, MEK, and p38 MAP kinase, respectively, all of which are involved in cellular responses and RNA processing events that R3HDM4 could regulate. Lastly, Bisindolylmaleimide I and 17-AAG interfere with protein kinase C and Hsp90, respectively, impacting protein folding and signaling pathways, further suggesting a multi-angled approach in modulating R3HDM4's activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. While broadly acting, it can inhibit specific kinases that phosphorylate substrates involved in RNA metabolism and processing, thereby inhibiting the cellular processes that R3HDM4 is involved in. | ||||||
K-252a | 99533-80-9 | sc-200517 sc-200517B sc-200517A | 100 µg 500 µg 1 mg | $129.00 $214.00 $498.00 | 19 | |
K252a is a kinase inhibitor with a broad spectrum of targets. It can inhibit protein kinases that are involved in signal transduction pathways leading to RNA metabolism, potentially leading to the functional inhibition of R3HDM4 in processes such as RNA binding or splicing. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
This compound inhibits CDK9 and P-TEFb, which are involved in transcription regulation. Inhibiting these kinases can disrupt the transcriptional processes and RNA polymerase II activity that R3HDM4 may be functionally associated with. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in transcriptional control and stress responses. Through the inhibition of JNK, SP600125 can disrupt signaling pathways necessary for the proper function of R3HDM4 in stress-related RNA processing. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can disrupt cellular signaling required for R3HDM4's regulation of RNA metabolism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that can impede the MAPK/ERK pathway. This can lead to the inhibition of downstream processes including those that involve R3HDM4's activity in RNA binding and processing. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K), which impacts various signaling pathways, including those that may regulate the RNA-binding activity of R3HDM4. By inhibiting PI3K, LY294002 can disrupt the function of R3HDM4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key regulatory kinase. mTOR is involved in mRNA translation and cell growth; its inhibition by Rapamycin can disrupt processes potentially linked to R3HDM4 activity in RNA metabolism. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, Wortmannin can lead to a decrease in phosphorylation of downstream targets within the PI3K/AKT/mTOR pathway, which can inhibit R3HDM4's role in RNA-related processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in stress responses and RNA processing. By inhibiting p38 MAP kinase, SB203580 can inhibit cellular processes that are necessary for R3HDM4 to function in stress-related RNA metabolism. | ||||||